SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)

Simple item page
dc.conference.dateMAY 05-08, 2021
dc.conference.titleESMO Breast Cancer Virtual Congress
dc.contributor.authorCiruelos, E.
dc.contributor.authorSalvador Bofill, F. J.
dc.contributor.authorPerello Martorell, A.
dc.contributor.authorAlba Conejo, E.
dc.contributor.authorGonzalez-Farre, X.
dc.contributor.authorPalacios-Ozores, P.
dc.contributor.authorMerino, M.
dc.contributor.authorVillagrasa, P.
dc.contributor.authorVila Navarro, E.
dc.contributor.authorPascual, T.
dc.contributor.authorPrat, A.
dc.contributor.authorPernas Simon, S.
dc.contributor.authoraffiliation[Ciruelos, E.] Univ Hosp 12 Octubre, Dept Med Oncol, SOLTI Breast Canc Res Grp, Madrid, Spain
dc.contributor.authoraffiliation[Salvador Bofill, F. J.] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Perello Martorell, A.] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Alba Conejo, E.] Hosp Univ Virgen de la Victoria, Dept Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Gonzalez-Farre, X.] Hosp Gen Cataluna, Dept Med Oncol, SOLTI Breast Canc Res Grp, Sant Cugat Del Valles, Spain
dc.contributor.authoraffiliation[Palacios-Ozores, P.] CHUS Complejo Hosp Univ Santiago de Compostela SE, Dept Oncol, Santiago De Compostela, Spain
dc.contributor.authoraffiliation[Merino, M.] Hosp Infanta Sofia, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Villagrasa, P.] Sci Dept, SOLTI Breast Canc Res Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Vila Navarro, E.] Sci Dept, SOLTI Breast Canc Res Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Pascual, T.] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Breast Canc Res Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Prat, A.] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Breast Canc Res Grp, Barcelona, Spain
dc.contributor.authoraffiliation[Pernas Simon, S.] Hosp Duran & Reynals, Med Oncol Breast Unit, SOLTI Breast Canc Res Grp, ICO Inst Catala Oncol Hospitalet, Lhospitalet De Llobregat, Spain
dc.contributor.funderPfizer
dc.date.accessioned2025-01-07T15:22:57Z
dc.date.available2025-01-07T15:22:57Z
dc.date.issued2021-05-08
dc.identifier.doi10.1016/j.annonc.2021.03.087
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753421009650/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27091
dc.identifier.wosID648924400075
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS52-S53
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleSOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía